Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Congenital Vascular Malformations
Personalized Treatment Before a Planned Pregnancy
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Tumors of the Calcaneus
Diagnostic Challenges of Rare Heel Tumors
- Upper GI Tract Bleeding: Hematemesis, Hematochezia, or Melena?
From Risk Stratification to Post-Endoscopic Management
- Obesity, Nutrition, and Mental Health
Depression, Binge Eating, Internalized Stigma
- From Hypertension to Heart Failure?
When and how to intervene
- Switzerland's First PTH Replacement Therapy